Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 14/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071372 | 0.92 | GSK3B (0.43) | MPLALDH1A1KMT2AKDM4EHPGD | |
| SCHEMBL6071222 | 0.89 | MPL (0.48) | MPLKMT2ARETKDM4EPARP1 | |
| SCHEMBL6071082 | 0.86 | MPL (0.54) | MPLALDH1A1KMT2ARETKDM4E | |
| SCHEMBL6071018 | 0.81 | KMT2A (0.42) | MPLALDH1A1KMT2AKDM4EHPGD | |
| SCHEMBL6071286 | 0.77 | GSK3B (0.45) | MPLALDH1A1KMT2AKDM4EHPGD | |
| SCHEMBL6071062 | 0.77 | PARP1 (0.38) | MPLALDH1A1KDM4EHPGDPARP1 | |
| SCHEMBL6070880 | 0.75 | MPL (0.57) | MPLPARP1DYRK1A | |
| SCHEMBL6071199 | 0.68 | AURKA (0.53) | MPLALDH1A1KMT2AKDM4EGAA | |
| SCHEMBL6449055 | 0.67 | HSD17B10 (0.59) | MPLALDH1A1KMT2AKDM4EGAA | |
| SCHEMBL6070734 | 0.66 | GSK3B (0.47) | MPLALDH1A1KMT2AKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K1, MAP3K19, MAP3K20 | MPL 1056/4885ALDH1A1 4446/4885KMT2A 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.